Neuro Spectrum Insights, Inc.

S-1/A amended

Price $4.50 · Range $4.00 to $5.00 · 3,750,000 shares · Gross proceeds $16,875,000

Neuro Spectrum Insights, Inc. is conducting its initial public offering (IPO) for 3,750,000 shares of common stock at an expected price range of $4.00 to $5.00 per share. The company develops GyriCalc, a proprietary software tool for diagnosing autism via MRI analysis, which received FDA marketing clearance in July 2025. The offering is led by Network 1 Financial Securities, Inc., a firm owned by a company shareholder. The IPO aims to fund commercialization efforts in the U.S. and Canada, where GyriCalc faces reimbursement and regulatory challenges.

S-1/A amended

Neuro Spectrum Insights, Inc. is preparing to commercialize GyriCalc™, a patented software for diagnosing autism via MRI analysis. The company seeks to raise capital through an IPO, with shares expected to be listed on the NYSE. It has secured FDA marketing clearance in the U.S. and is pursuing market entry in Canada through government and non-profit engagement. The offering includes both an initial public offering and a resale component, with Network 1 Financial Securities Inc. as the sole underwriter.

S-1/A amended

NeuroSpectrum Insights, Inc. is a medical device company commercializing GyriCalc™, a proprietary software for diagnosing autism via MRI analysis. The company secured FDA marketing clearance in July 2025 and is pursuing market entry in the U.S. and Canada. In Canada, it plans to engage government departments and non-profits to facilitate reimbursement and clinical adoption, though no regulatory approval is required. The company remains revenue-neutral, focusing on product launch and market penetration.

S-1/A amended

Neuro Spectrum Insights, Inc. is conducting an initial public offering (IPO) of its common stock, with the goal of commercializing its proprietary software solution, GyriCalc, designed to assist in diagnosing autism through MRI analysis. The company received FDA marketing clearance for GyriCalc in July 2025 and is seeking NYSE listing. The offering includes a public offering of shares and a potential resale by stockholders, with Network 1 Financial Securities Inc. acting as the sole book-running manager. The company has not yet generated revenue and focuses on market entry in the U.S. and Canada, with plans to expand to other neurological conditions.

S-1 filed

NeuroSpectrum Insights, Inc. is seeking to raise capital through an initial public offering (IPO) of its common stock, with shares expected to be listed on the NYSE under the symbol [*]. The company develops GyriCalc, a patented software tool for diagnosing autism via MRI analysis, and plans to expand to other neurological conditions. The filing includes a public offering and a resale offering by existing shareholders, with underwriters including Network 1 Financial Securities, Inc. The company has not yet generated revenue and anticipates FDA approval for GyriCalc in 2025.

DRS filed

Neuro Spectrum Insights, Inc. is preparing to commercialize GyriCalc, a patented medical device software that uses MRI data to analyze brain structures for diagnosing neurological disorders like autism. The company is conducting an initial public offering (IPO) with a proposed share price range of $[•] to $[•], aiming to list on Nasdaq under the symbol "[*]". The offering includes a public offering prospectus and a resale prospectus for existing shareholders, with underwriters including Network 1 Financial Securities, Inc. The filing highlights risks related to regulatory approval, market competition, and reliance on a single product.